FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387125265> ?p ?o ?g. }

• W4387125265 abstract "<div>AbstractPurpose:<p>This was a Phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to establish the safety profile, recommended Phase 2 dose (RP2D), pharmacokinetics profile, and clinical activity of SRA737.</p>Patients and Methods:<p>Patients with advanced solid tumors were enrolled into dose-escalation cohorts and treated in 28-day cycles with oral SRA737 on days 2, 3, 9, 10, 16, and 17, and intravenous gemcitabine on days 1, 8, and 15. Treatment was continued until progression. Each expansion cohort included up to 20 patients with specific genetically defined tumors.</p>Results:<p>The RP2D was determined to be 500 mg SRA737 combined with low-dose (250 mg/m²) gemcitabine. Of 143 enrolled patients, 77 were treated at doses of at least 500 mg SRA737 combined with 250 mg/m² gemcitabine. Common toxicities of nausea, vomiting, fatigue, and diarrhea were primarily mild to moderate, and rarely led to treatment discontinuation. Anemia, neutropenia, and thrombocytopenia were grade ≥3 in 11.7%, 16.7%, and 10% of patients treated at the RP2D, respectively. The objective response rate (ORR) was 10.8% overall and notably the ORR in anogenital cancer was 25%. Partial tumor responses were observed in anogenital cancer, cervical cancer, high-grade serous ovarian cancer, rectal cancer, and small cell lung cancer.</p>Conclusions:<p>SRA737 in combination with low-dose gemcitabine was well tolerated with lower myelotoxicity than has been seen at standard doses of gemcitabine or with other combinations of Chk1 inhibitors with gemcitabine. Tumor responses were observed in anogenital and other solid tumors.</p></div>" @default.
• W4387125265 created "2023-09-29" @default.
• W4387125265 creator A5006299989 @default.
• W4387125265 creator A5012989377 @default.
• W4387125265 creator A5013760636 @default.
• W4387125265 creator A5020139920 @default.
• W4387125265 creator A5026821034 @default.
• W4387125265 creator A5032401979 @default.
• W4387125265 creator A5033090749 @default.
• W4387125265 creator A5048419838 @default.
• W4387125265 creator A5052216285 @default.
• W4387125265 creator A5059303252 @default.
• W4387125265 creator A5068550336 @default.
• W4387125265 creator A5069485042 @default.
• W4387125265 creator A5080593577 @default.
• W4387125265 creator A5080693514 @default.
• W4387125265 creator A5088144652 @default.
• W4387125265 creator A5089670001 @default.
• W4387125265 date "2023-09-28" @default.
• W4387125265 modified "2023-10-18" @default.
• W4387125265 title "Data from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer" @default.
• W4387125265 doi "https://doi.org/10.1158/1078-0432.c.6857419" @default.
• W4387125265 hasPublicationYear "2023" @default.
• W4387125265 type Work @default.
• W4387125265 citedByCount "0" @default.
• W4387125265 crossrefType "posted-content" @default.
• W4387125265 hasAuthorship W4387125265A5006299989 @default.
• W4387125265 hasAuthorship W4387125265A5012989377 @default.
• W4387125265 hasAuthorship W4387125265A5013760636 @default.
• W4387125265 hasAuthorship W4387125265A5020139920 @default.
• W4387125265 hasAuthorship W4387125265A5026821034 @default.
• W4387125265 hasAuthorship W4387125265A5032401979 @default.
• W4387125265 hasAuthorship W4387125265A5033090749 @default.
• W4387125265 hasAuthorship W4387125265A5048419838 @default.
• W4387125265 hasAuthorship W4387125265A5052216285 @default.
• W4387125265 hasAuthorship W4387125265A5059303252 @default.
• W4387125265 hasAuthorship W4387125265A5068550336 @default.
• W4387125265 hasAuthorship W4387125265A5069485042 @default.
• W4387125265 hasAuthorship W4387125265A5080593577 @default.
• W4387125265 hasAuthorship W4387125265A5080693514 @default.
• W4387125265 hasAuthorship W4387125265A5088144652 @default.
• W4387125265 hasAuthorship W4387125265A5089670001 @default.
• W4387125265 hasConcept C121608353 @default.
• W4387125265 hasConcept C126322002 @default.
• W4387125265 hasConcept C143998085 @default.
• W4387125265 hasConcept C197934379 @default.
• W4387125265 hasConcept C2776256026 @default.
• W4387125265 hasConcept C2776694085 @default.
• W4387125265 hasConcept C2777063308 @default.
• W4387125265 hasConcept C2778375690 @default.
• W4387125265 hasConcept C2780258809 @default.
• W4387125265 hasConcept C2780580376 @default.
• W4387125265 hasConcept C71924100 @default.
• W4387125265 hasConcept C90924648 @default.
• W4387125265 hasConceptScore W4387125265C121608353 @default.
• W4387125265 hasConceptScore W4387125265C126322002 @default.
• W4387125265 hasConceptScore W4387125265C143998085 @default.
• W4387125265 hasConceptScore W4387125265C197934379 @default.
• W4387125265 hasConceptScore W4387125265C2776256026 @default.
• W4387125265 hasConceptScore W4387125265C2776694085 @default.
• W4387125265 hasConceptScore W4387125265C2777063308 @default.
• W4387125265 hasConceptScore W4387125265C2778375690 @default.
• W4387125265 hasConceptScore W4387125265C2780258809 @default.
• W4387125265 hasConceptScore W4387125265C2780580376 @default.
• W4387125265 hasConceptScore W4387125265C71924100 @default.
• W4387125265 hasConceptScore W4387125265C90924648 @default.
• W4387125265 hasLocation W43871252651 @default.
• W4387125265 hasOpenAccess W4387125265 @default.
• W4387125265 hasPrimaryLocation W43871252651 @default.
• W4387125265 hasRelatedWork W1973342136 @default.
• W4387125265 hasRelatedWork W2002502340 @default.
• W4387125265 hasRelatedWork W2022556905 @default.
• W4387125265 hasRelatedWork W2061167989 @default.
• W4387125265 hasRelatedWork W2387790385 @default.
• W4387125265 hasRelatedWork W2393784267 @default.
• W4387125265 hasRelatedWork W2394317912 @default.
• W4387125265 hasRelatedWork W3036882192 @default.
• W4387125265 hasRelatedWork W4251165208 @default.
• W4387125265 hasRelatedWork W2183331092 @default.
• W4387125265 isParatext "false" @default.
• W4387125265 isRetracted "false" @default.
• W4387125265 workType "article" @default.